Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Want to see CAI full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.01Last Year’s EPS
-7.97Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial and financial momentum: substantial revenue and ASP growth, materially improved gross margins, positive adjusted EBITDA and free cash flow, meaningful balance sheet strength, multiple product launches, and encouraging MCED validation data. Headwinds are predominantly timing and phasing related—sales realignment effects on completed cases, short-term Pharma revenue cadence, and elevated near-term investment and CapEx ahead of new product launches. Reimbursement dynamics remain a watch item despite management's confident position. Overall, the positive operational and financial progress and strategic initiatives outweigh the timing and investment-related challenges.Company Guidance
Record Revenue Growth
Total revenue of $216.0M in Q1 2026, up 79% year-over-year, driven primarily by molecular profiling services.
Molecular Profiling Revenue Surge
Molecular profiling services revenue of $211.0M, up 85% year-over-year, supported by both volume growth and higher ASPs.
Volume and Exit Run-Rate Improvement
Completed 52,800 therapy selection cases in Q1, up 15% year-over-year. Exit run-rate for February–March implied ~56,000 completed cases and management expects Q2 >58,000 cases (~10% sequential growth).
Substantial ASP and Gross Margin Expansion
Clinical ASP increased markedly (clinical ASP up 61% YoY). Tissue ASP increased ~70% to over $4,300 and blood ASP increased ~14% to just under $2,500. Molecular profiling gross margin improved to 65% GAAP (from 47% in prior-year Q1), an increase of ~1,800 basis points YoY.
Profitability and Cash Generation
Positive adjusted EBITDA of $26M and positive free cash flow of roughly $22.5–$23M in the quarter; fourth consecutive quarter with both metrics positive.
Strong Balance Sheet and Financing Flexibility
Cash on hand slightly above $825M (up ~$23.4M in the quarter). Refinance completed: new $400M facility led by Blue Owl & Blackstone, saves ~ $6M in annual interest, extends maturity to April 2031 and includes $300M delayed draw term loan for acquisitions.
Large and Growing Data & Commercial Footprint
Platform dataset surpassed 1.07M profiled cases (including >677k whole exomes, 728k whole transcriptomes, ~790k matched profiles). Supporting >6,100 ordering oncologists; ~70% of orders via EHR/portal; >3,000 physicians using EMR integrations.
Product Launches and Pipeline Progress
Launched Caris ChromaSeq (Apr 1) and Caris MI Clarity; Caris ChromaSeq received MolDX pricing at $3,228. Caris Detect (MCED) achieved CLIA validation readout and is in beta/commercial prep with Everlywell.
Caris Detect ACHIEVE-1 Performance
ACHIEVE-1: overall stage I–II sensitivity 60.3% and asymptomatic specificity 99.2% in a 3,014-subject high-risk cohort. Stage sensitivities: Stage I 56.8%, Stage II 67.7%, Stage III 79.0%, Stage IV 98.6%. Cancer-type sensitivities (stage I–II) include breast 53.7%, prostate 74.1%, lung 73.4%, head & neck 81.3%, pancreatic 70%.
Commercial Momentum in Caris Assure and Sales Expansion
Caris Assure volume grew 58% year-over-year and blood volume growth guidance remains high (high-50s to low-60s % range). Field organization expanded from 82 to 146 territories; >270 sales reps at quarter end progressing toward a ~300-person goal, with activations in Feb–Mar up ~20% YoY in same period.
CAI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CAI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $19.84 | $16.15 | -18.60% |
Feb 26, 2026 | $19.24 | $20.14 | +4.68% |
Nov 05, 2025 | $29.21 | $24.61 | -15.75% |
Aug 12, 2025 | $32.46 | $34.28 | +5.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Caris Life Sciences, Inc. (CAI) report earnings?
Caris Life Sciences, Inc. (CAI) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is Caris Life Sciences, Inc. (CAI) earnings time?
Caris Life Sciences, Inc. (CAI) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAI EPS forecast?
CAI EPS forecast for the fiscal quarter 2026 (Q2) is 0.01.